12:00 AM
 | 
Jan 14, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Absorb bioresorbable vascular scaffold: Pivotal trial started

Abbott began the U.S. pivotal Absorb III trial to compare Absorb bioresorbable vascular scaffold vs. the company's marketed Xience V or Xience Prime everolimus-eluting coronary stent systems in about 2,250 patients with de novo native...

Read the full 174 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >